

Last updated: Jan. 2020.

Mary Ann Liebert, Inc.  publishers

**Biotechnology
and
Regenerative
Medicine**



**Biomedical
Research**



**Clinical
Medicine**



**Engineering
and
Technology**



**Environmental Studies
Integrative Medicine
Law and Policy
Nursing
Public Health
Surgery**



The Leading Independent Publisher of Specialty STM content

<https://www.liebertpub.com/>

EBSCO

EBSCO Korea

About **Mary Ann Liebert**

- 주제분야 : AIDS, 유전자 치료, 생명의학, 공학, 임상의학, 법학, 환경과학
- 원문정보 제공 년도 : 1980년 - 현재 (저널 별로 다양)
- 저널종수 : 기본 (73 종) / 신규 타이틀 패키지 (18종)
- 서비스제공주소 : <https://www.liebertpub.com>

Mary Ann Liebert, Inc. publishers

- ① 1980년에 설립되어 AIDS, 유전자 치료, 생물복제 등의 전문분야를 다룸.
- ② 생물공학 분야에서 주도적인 출판사로 손꼽히고 있음.

Mary Ann Liebert, Inc. publishers




Site Navigation

사이트 소개

Responsive Design

모바일 기기
반응형 웹 지원




별도의 어플리케이션
다운로드 없이
어떠한 기기에서도
Mary Ann Liebert
모든 콘텐츠에 대하여
쉽게 접근이 가능함.

Main Page

개인 계정으로 로그인 가능

특정 콘텐츠 검색이 가능함

홈페이지 내 어디서든지 로고를 누르면
다시 메인 페이지로 돌아갑니다.



“Publication” 메뉴에 마우스를 가져가면 드롭-다운메뉴가 아래와 같이 제공됨

Publications
drop-down
menu
발간물

The screenshot shows the Mary Ann Liebert, Inc. website. The top navigation bar is dark red with the company logo on the left and a list of links on the right: PUBLICATIONS, AUTHORS, LIBRARIANS, OPEN ACCESS, ADVERTISING, and CORPORATE CAPABILITIES. The 'PUBLICATIONS' link is highlighted with a yellow circle. Below the navigation bar, there are three main sections: 'Journal Collections' with a list of journals, 'Publications by Type' with a list of publication types, and 'All Publications' with a link to 'A to Z'. A red arrow points from the 'All Publications' section to the text '모든 발간물과 A-Z 디렉토리'. At the bottom of the page, there are four sections: 'Authors', 'Librarians', 'Open Access', and 'Corporate Capabilities'. The Windows taskbar is visible at the bottom of the screen.

Mary Ann Liebert, Inc. publishers

컬렉션 단위

타입별

PUBLICATIONS

AUTHORS

LIBRARIANS

OPEN ACCESS

ADVERTISING

CORPORATE CAPABILITIES

Journal Collections

Biomedical Research

Biotechnology and Regenerative Medicine

Integrative Medicine

Environmental Studies

Law and Policy

Public Health

Nursing

Clinical Medicine

Technology and Engineering

Surgery

Publications by Type

Journals (Print/Online)

Journals (Open Access)

Journals (Video)

Books

e-Books

Trade Magazines

Newsletters

e-Newsletters

CD-ROMs

All Publications

A to Z

Recommend a Title to Your Library

모든 발간물과 A-Z 디렉토리

Public Health Surgery

Authors

Publishing with Mary Ann Liebert, Inc. delivers end-to-end benefits from the time of submission through to publication and beyond.

Librarians

We welcome the opportunity to work with you and your institution. Find everything you need to get the most out of Liebert journals in your library and to keep your collection up-to-date.

Open Access

Liebert Open Access incorporates our open access journals, as well as open access articles published in our subscription journals. All content published by Liebert Open Access is freely available online for everyone to

Corporate Capabilities

Take your brand to the next level with custom publishing programs from Mary Ann Liebert Inc., publishers.

https://home.liebertpub.com/publications

9:08 AM 4/24/2018

Methods of Browsing Our Journals

컬렉션/ A-Z/ 유형별 브라우징 가능

The screenshot shows the Mary Ann Liebert, Inc. publishers website. The header includes the logo and navigation links: PUBLICATIONS, AUTHORS, LIBRARIANS, OPEN ACCESS, ADVERTISING, and CORPORATE CAPABILITIES. Below the header, there's a section titled "Groundbreaking Publications" with a description of the portfolio. Further down, a banner reads "Browse our complete catalog or by subject area to learn more about our unparalleled publications". Below this banner, three overlapping circles highlight the browsing methods: "Journal Collections", "Titles A-Z", and "Publications by Type". Each circle contains a brief description of the method and a link to browse.

Journal Collections
More than 90 peer-reviewed journals in the most promising areas of biomedical research, biotechnology and regenerative medicine, clinical medicine and surgery, public health, technology and engineering, environmental studies, and law and policy.
[Browse collections...](#)

Titles A-Z
View the complete alphabetized catalog of Mary Ann Liebert publications with direct access to in-depth publication information and published content.
[Browse A-Z...](#)

Publications by Type
In addition to our industry leading peer-reviewed journals, the full Mary Ann Liebert catalog of publications includes books, ebooks, trade magazines, newsletters, and more!
[Browse by type...](#)

Mary Ann Liebert 출판사의 content 를
학술분야, A to Z, Content 타입 별로
브라우징 가능하도록 화면 구성
각 메뉴에 쉽게 접근할 수 있도록 구성

Browse by Collections

저널 컬렉션



생물의학, 생명공학, 약학,
환경 연구, 정책, 법, 보건환경,
간호, 임상의학, 공학기술, 수술 등
주제분야별 저널 브라우징 가능

Browse Journals A - Z

A-Z List

PUBLICATIONS PUBLICATIONS A-Z JOURNAL COLLECTIONS PUBLICATION BY TYPE RECOMMEND A TITLE


Publication List A-Z

Titles beginning with: 3 | A | B | C | D | E | F | G | H | I | J | L | M | N | O | P | R | S | T | V | W | Z | Show All

19 Articles You Can Use: Series of Planned Giving	MORE INFO	이용상태 확인
3D Printing and Additive Manufacturing	MORE INFO	ONLINE ACCESS
Advances in Preschool Psychopharmacology	MORE INFO	ONLINE ACCESS
Advances in Preschool Psychopharmacology: e-Book	MORE INFO	
Advances in Tissue Engineering, Volume 1: Angiogenesis	MORE INFO	ONLINE ACCESS
Advances in Tissue Engineering, Volume 1: e-book	MORE INFO	
Advances in Tissue Engineering, Volume 2: e-book	MORE INFO	
Advances in Tissue Engineering, Volume 2: Stem Cells	MORE INFO	ONLINE ACCESS
Advances in Wound Care	MORE INFO	ONLINE ACCESS
Advances in Wound Care, Volume 1	MORE INFO	ONLINE ACCESS
Advances in Wound Care, Volume 2	MORE INFO	ONLINE ACCESS
Advances in Wound Care, Volume 2 e-book	MORE INFO	
Advances in Wound Care: Volume 1: e-book	MORE INFO	
AIDS Patient Care and STDs	MORE INFO	ONLINE ACCESS
AIDS Research and Human Retroviruses	MORE INFO	ONLINE ACCESS

Browse by Type

타입별




저널, 단행본, eBook, 뉴스레터 등
자료 형태별 브라우징 가능

Search
검색


Search

Mary Ann Liebert 사이트 내 어디서든 우측 상단의 돋보기 모양을 클릭하면 아래와 같은 검색창이 나타남



The screenshot shows the top navigation bar of the Mary Ann Liebert website. On the left is the logo "Mary Ann Liebert, Inc. publishers" with a stylized leaf icon. On the right, it says "brought to you by Mary Ann Liebert, Inc., publishers" followed by a magnifying glass icon, a user icon, and a shopping cart icon. Below this is a horizontal menu with links: PUBLICATIONS, AUTHORS, LIBRARIANS, OPEN ACCESS, ADVERTISING, and CORPORATE CAPABILITIES. A red arrow points from the text above to the magnifying glass icon. Below the menu is a search bar with a dropdown menu set to "Anywhere" and a search input field containing the placeholder text "Enter words / phrases / DOI / ISBN / keywords / authors / etc". To the right of the input field is a magnifying glass icon and a link to "Advanced Search".

- 사이트 내 모든 곳과 인용 등 선택하여 검색이 가능
- 단어/ 문구/ DOI / ISBN/ 키워드 / 저자 등의 검색을 할 수 있음



This screenshot shows the same website header as the previous one, but with the search bar expanded. The dropdown menu is now set to "Citation" and the search input field is empty. To the right of the input field are several filter buttons: "Journal", "Year", "Volume", "Issue", and "Page", each with a magnifying glass icon. To the right of these buttons is a link to "Advanced Search". A red arrow points from the text below to the "Advanced Search" link.

더 나은 검색결과를 위하여 Advanced 검색

Advanced Search – 상세검색

Mary Ann Liebert, Inc. publishers

검색기록 / 저장된 검색결과 확인

PUBLICATIONS AUTHOR

Advanced Search Search History Saved Searches

모두/ 서명/ 저자/ 주제어/ 초록 등을 선택하여 검색

Anywhere

Anywhere

Title

Author

Keywords

Abstract

Enter Search term And / Or / Not 연산자 활용 가능

+

추가 검색 조건을 넣을 수 있음

e.g. Journal of Theoretical Biology 저널명 등을 입력할 수 있음

All dates

Last Select

Custom range Month Year Month Year

출판 년도 한정 검색

Advanced

include Articles in Ahead of Print

이미 출판된 논문을 포함하여 검색할 것인지 선택

Search

Search Results

클릭하여
검색결과를 저장

The screenshot shows the search results page for 'Genetic Editing' on the Mary Ann Liebert, Inc. website. The page is divided into several sections:

- Header:** Mary Ann Liebert, Inc. publishers logo and navigation links (PUBLICATIONS, AUTHORS, LIBRARIANS, OPEN ACCESS, ADVERTISING).
- Search Bar:** A search bar with the text 'Genetic Editing' and a dropdown menu set to 'Anywhere'. An 'Advanced Search' link is also present.
- Filters:** A sidebar on the left titled 'NARROW RESULTS' showing 'FILTERS APPLIED' (Last Year) and 'AUTHOR' (Flotte, Terence R; Wilson, James M; Davies, Kevin; Philiniridis, Alex).
- Results:** The main content area displays 'RESULTS: 1 - 20 of 383 Genetic Editing'. It includes a 'REFINE SEARCH' dropdown, 'PER PAGE' options (20, 50, 100), and a 'SORT: RELEVANCE' dropdown.
- Article Listings:** Three articles are listed with their titles, authors, and publication dates. Each article has an 'Abstract' link.

A red arrow points from the Korean text '클릭하여 검색결과를 저장' to the 'Follow results' link in the top right corner of the results section.

Research Article	255
Review Article	50
Editorial	27
Letter	17
Abstract	12
MORE (6)	


AUTHOR	
Flotte, Terence R	11
Wilson, James M	6
Davies, Kevin	5
Philiniridis, Alex	5

Recent Advances in Therapeutic Genome Editing in China
Yang Yang , Wang Qingnan , Li Qian , Men Ke , He Zhiyao , Deng Hongxin , Ji Weizhi , Wei Yuquan
Published Online: 01 Feb 2018 https://doi.org/10.1089/hum.2017.210
Abstract

Transgenerational CRISPR-Cas9 Activity Facilitates Multiplex Gene Editing in Allopolyploid Wheat
Wang Wei , Pan Qianli , He Fei , Akhunova Alina , Chao Shiaoan , Trick Harold , Akhunov Eduard
Published Online: 01 Feb 2018 https://doi.org/10.1089/crispr.2017.0010
Abstract

Adenosine-to-Inosine RNA Editing in Health and Disease
Gatsiou Aikaterini , Vlachogiannis Nikolaos , Lunella Federica Francesca , Sachse Marco , Stellos Konstantinos
Published Online: 01 Feb 2018 https://doi.org/10.1089/hum.2017.210
Abstract

Refine Search – 결과 내 검색



The screenshot shows a search results interface. On the left, under 'NARROW RESULTS', there are filters applied: 'Review Article' and 'Last Year'. Below this is a list of authors and their counts, followed by a 'PUBLICATION' section listing various topics and their counts. On the right, the main search results area is titled 'TITLES AND WEBSITE RESULTS' and 'ARTICLES AND PUBLISHED CONTENT'. It shows 'RESULTS: 1 - 20 of 50 Genetic Editing'. A red arrow points from the 'REFINE SEARCH' section on the left to the 'REFINE SEARCH' section on the right. The 'REFINE SEARCH' section on the right includes options for 'PER PAGE' (20, 50, 100) and 'SORT: RELEVANCE'. Below this are tabs for 'Advanced Options', 'Search History', and 'Saved Searches'. The 'Advanced Options' tab is active, showing search criteria: 'Anywhere' (dropdown), 'Genetic Editing' (text input), 'Anywhere' (dropdown), 'Enter Search term' (text input), 'Published in' (text input with example 'e.g. Bioelectronics in Medicine'), and 'Publication Date' (radio buttons for 'All dates', 'Last', and 'Custom range'). The 'Last' option is selected, and a 'year' dropdown is visible. The 'Custom range' option has four dropdowns for 'Month', 'Year', 'Month', and 'Year'. A 'Search' button is at the bottom right.

NARROW RESULTS

FILTERS APPLIED

Review Article × Last Year ×

Clear all

AUTHOR

Chuah, Marinee K 2

Dandara, Collet 2

Kunej, Tanja 2

VandenDriessche, Thierry 2

Abuharfeil, Nizar Mohammad 1

MORE (95) ▾

PUBLICATION

Human Gene Therapy Clinical Development 18

Human Gene Therapy Methods 18

Human Gene Therapy 16

Antioxidants & Redox Signaling 8

The CRISPR Journal 4

TITLES AND WEBSITE RESULTS

ARTICLES AND PUBLISHED CONTENT

RESULTS: 1 - 20 of 50 Genetic Editing

Follow results: 🔍 📡

REFINE SEARCH ▾

PER PAGE: 20 50 100 | SORT: RELEVANCE ▾

Advanced Options Search History Saved Searches

Anywhere ▾ Genetic Editing +

Anywhere ▾ Enter Search term +

Published in e.g. Bioelectronics in Medicine

Publication Date


☐ All dates

☒ Last year ▾


☐ Custom range Month ▾ Year ▾ Month ▾ Year ▾

Search

Search History – 검색 히스토리



Saved Searches – 검색결과 저장



Advanced Search

Search History

Saved Searches

PUBLICATIONS

AUTHORS

LIBRARIANS

OPEN ACCESS

ADVANCED SEARCH

Saved Search Name	Frequency	Last run on		
Genetic Editing	D	May 1, 2018	RUN	DELETE

Journal Pages

저널

Journal Landing Page

개별 저널 페이지

A

B

C

D

E

F



Journal of Neurotrauma

Editor-in-Chief: John T. Povlishock, PhD

ISSN: 0897-7151 | Online ISSN: 1557-9042 | 24 Issues Annually | Current Volume: 35

Latest Impact Factor* is **5.190** *2016 Journal Citation Reports® (Clarivate Analytics, 2017)

The only peer-reviewed journal focused exclusively on traumatic brain and spinal cord injury, with far-reaching coverage ranging from the basic biology of trauma to clinical trials aimed at improving long-term care and recovery...

[View Aims & Scope...](#)

Search



Subscribe/Renew



Recommend This Title



Sign Up for TOC Alerts



Submit a Paper



Share with a Colleague



A 현재 발간 이슈

B 모든 이슈

C 구독/갱신 관련

D 논문 투고 관련 정보

E 알람 설정

F 광고 관련

Featured Content

PRESS

Does Concussion Recovery and Symptom Severity Differ Between Men and Women?

[READ MORE](#)

PRESS

Best Practices Lacking for Managing Traumatic Brain Injury in Geriatric Patients




Current
Issue
Journal View
현재 발간
이슈

Mary Ann Liebert, Inc. publishers

PUBLICATIONS AUTHORS LIBRARIANS OPEN ACCESS

PUBLICATION HOME SUBSCRIBE/ORDER FOR AUTHORS ALERTS ADVERTISE



Journal of Neurotrauma
Editor-in-Chief: John T. Povlishock, PhD

ISSN: 0897-7151 | Online ISSN: 1557-9042 | 24 Issues Annually | Current Volume: 35

Latest Impact Factor* is 5.19 *2016 Journal C

The only peer-reviewed journal focused exclusively on traumatic brain and spinal cord injury, with far-reaching coverage ranging from the basic biology of trauma to clinical trials aimed at improving long-term care and recovery.

Submit a Paper

Subscribe/Renew

All Issues

Reprints/ePrints

논문 투고

구독 및 갱신

모든 이슈

VOLUME 35, ISSUE 9 / MAY 2018

Open Access

Rho Inhibitor VX-210 in Acute Traumatic Subaxial Cervical Spinal Cord Injury: Design of the SPinal Cord Injury Rho INhibition InvestiGation (SPRING) Clinical Trial

Fehlings Michael G., Kim Kee D., Aarabi Bizhan, Rizzo Marco, Bond Lisa M., McKerracher Lisa, Vaccaro Alexander R., and Okonkwo David O.

Pages: 1049–1056 | Published Online: 1 March 2018

<https://doi.org/10.1089/neu.2017.5434>

Preview Abstract

Abstract | Full text | PDF | Permissions

원문 / PDF 저장

Parallel Evaluation of Two Potassium Channel Blockers in Restoring Conduction in Mechanical Spinal Cord

<https://serve.liebertpub.com/link/NEU/5/252/7804/8818/192.168.2.101/>

Secure your access to

Journal of Neurotrauma

REQUEST A SUBSCRIPTION

Author Benefits Program
Mary Ann Liebert, Inc.

Article Pages

아티클



Figures



References



Related



Details

Rho Inhibitor VX-210 in Acute Traumatic Subaxial Cervical Spinal Cord Injury: Design of the SPinal Cord Injury Rho INhibition InvestiGation (SPRING) Clinical Trial


Fehlings Michael G., Kim Kee D., Aarabi Bizhan, Rizzo Marco, Bond Lisa M., McKerracher Lisa, Vaccaro Alexander R., and Okonkwo David O.

Published Online: 1 May 2018 | <https://doi.org/10.1089/neu.2017.5434>

[목차 / 원문보기](#)[Sections](#) [View Article](#)[추천 & 공유](#)[Tools](#) [Share](#)

Abstract 초록

Traumatic spinal cord injury (SCI) is associated with a lifetime of disability stemming from loss of motor, sensory, and autonomic functions; these losses, along with increased comorbid sequelae, negatively impact health outcomes and quality of life. Early decompression surgery post-SCI can enhance patient outcomes, but does not directly facilitate neural repair and regeneration. Currently, there are no U.S. Food and Drug Administration–approved pharmacological therapies to augment motor function and functional recovery in individuals with traumatic SCI. After an SCI, the enzyme, Rho, is activated by growth-inhibitory factors and regulates events that culminate in collapse of the neuronal growth cone, failure of axonal regeneration, and, ultimately, failure of motor and functional recovery. Inhibition of Rho activation is a potential treatment for injuries such as traumatic SCI. VX-210, an investigational agent, inhibits Rho. When administered extradurally after decompression (corpectomy or laminectomy) and stabilization surgery in a phase 1/2a study, VX-210 was well tolerated. Here, we describe the design of the SPRING trial, a multicenter, phase 2b/3, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of VX-210 (NCT02669849). A subset of patients with acute traumatic cervical SCI is currently being enrolled in the United States and Canada. Medical, neurological, and functional changes are evaluated at 6 weeks and at 3, 6, and 12 months after VX-210 administration. Efficacy will be assessed by the primary outcome measure, change in upper extremity motor score at 6 months post-treatment, and by secondary outcomes that include question-based and task-based evaluations of functional recovery.

[수치,도표](#) / [참고문헌](#) / [관련자료](#) / [논문정보](#)

VOLUME 35, ISSUE 9
MAY 2018

Information

© Michael G. Fehlings et al.

논문관련 정보

To cite this article:

Fehlings Michael G., Kim Kee D., Aarabi Bizhan, Rizzo Marco, Bond Lisa M., McKerracher Lisa, Vaccaro Alexander R., and Okonkwo David O..

Journal of Neurotrauma. May 2018. ahead of print

<http://doi.org/10.1089/neu.2017.5434>



Published in Volume: 35 Issue 9: May 1, 2018

Online Ahead of Print: March 1, 2018

Online Ahead of Editing: January 9, 2018

Keywords

관련 키워드

[motor recovery](#)[Rho inhibition](#)[spinal cord injury](#)[SPRING trial](#)[VX-210](#)

Publication History

Published online 1 May 2018



Rho Inhibitor VX-210 in Acute Traumatic Subaxial Cervical Spinal Cord Injury: Design of the SPinal Cord Injury Rho INhibition InvestiGation (SPRING) Clinical Trial

Fehlings Michael G. , Kim Kee D., Aarabi Bizhan, Rizzo Marco, Bond Lisa M., McKerracher Lisa, Vaccaro Alexander R., and Okonkwo David O.

Published Online: 1 May 2018 | <https://doi.org/10.1089/neu.2017.5434>



VOLUME 35, ISSUE 9
MAY 2018

Information

© Michael G. Fehlings et al.

Sections  View Article

 Tools

 Share

초 록


Abstract

 View PDF

PDF 보기

안 내

Introduction

 View PDF Plus

즐거 찾기

★ Add to favorites

자료 및 연구방법

Methods

참고문헌 다운

↓ Download Citations

결 론

Conclusions

참고문헌 보기

◇ Track Citations

Acknowledgments

Publication으로
돌아가기

ⓘ Back To Publication

Author Disclosure Statement



Facebook



Twitter



Linked In



Google+ Share



Reddit



Email

각종 SNS와 이메일
로 공유 가능

Bizhan, Rizzo Marco, Bond
Alexander R., and Okonkwo

is associated with a life-threatening condition, along with increased morbidity and mortality. Spinal cord injury (SCI) is a leading cause of disability, and the majority of SCI cases are caused by trauma. The current standard of care for SCI is surgical decompression and stabilization, followed by rehabilitation. However, the majority of patients with SCI do not achieve functional recovery. The Rho GTPase is a key regulator of neuronal growth and differentiation, and its inhibition has been shown to promote axonal regeneration and functional recovery in animal models of SCI. VX-210, a small molecule Rho inhibitor, has been shown to be effective in promoting axonal regeneration and functional recovery in animal models of SCI. In this study, we describe the design of the SPRING trial, a multicenter, phase 2b/3, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of VX-210 (NCT02669849). A subset of patients with acute traumatic cervical SCI is currently being enrolled in the United States and Canada. Medical, neurological, and functional changes are evaluated at 6 weeks and at 3, 6, and 12 months after VX-210 administration. Efficacy will be assessed by the primary outcome measure, change in upper extremity motor score at 6 months post-treatment, and by secondary outcomes that include question-based and task-based evaluations of functional recovery.

Keywords

motor recovery

Rho inhibition

spinal cord injury

SPRING trial

VX-210

Publication History

Published online 1 May 2018

Rho Inhibitor VX-210 in Acute Traumatic Subaxial Cervical Spinal Cord Injury: Design of the SPinal Cord Injury Rho INhibition InvestiGation (SPRING) Clinical Trial

Fehlings Michael G. ✉ Kim Kee D., Aarabi Bizhan, Rizzo Marco, Bond Lisa M., McKerracher Lisa, Vaccaro Alexander R., and Okonkwo David O.

Published Online: 1 May 2018 | <https://doi.org/10.1089/neu.2017.5434>

Sections View Article

Tools Share

Abstract

Traumatic spinal cord injury (SCI) is associated with a lifetime of disability stemming from loss of motor, sensory, and autonomic functions; these losses, along with increased comorbid sequelae, negatively impact health outcomes and quality of life. Early decompression surgery post-SCI can enhance patient outcomes, but does not directly facilitate neural repair and regeneration. Currently, there are no U.S. Food and Drug Administration–approved pharmacological therapies to augment motor function and functional recovery in individuals with traumatic SCI. After an SCI, the enzyme, Rho, is activated by growth-inhibitory factors and regulates events that culminate in collapse of the neuronal growth cone, failure of axonal regeneration, and, ultimately, failure of motor and functional recovery. Inhibition of Rho activation is a potential treatment for injuries such as traumatic SCI. VX-210, an investigational agent, inhibits Rho. When administered extradurally after decompression (corpectomy or laminectomy) and stabilization surgery in a phase 1/2a study, VX-210 was well tolerated. Here, we describe the design of the SPRING trial, a multicenter, phase 2b/3, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of VX-210 (NCT02669849). A subset of patients with acute traumatic cervical SCI is currently being enrolled in the United States and Canada. Medical, neurological, and functional changes are evaluated at 6 weeks and at 3, 6, and 12 months after VX-210 administration. Efficacy will be assessed by the primary outcome measure, change in upper extremity motor score at 6 months post-treatment, and by secondary outcomes that include question-based and task-based evaluations of functional recovery.




FIG. 1. SCI-mediated Rho (A) activation and (B) inhibition by VX-210. CSPG, chondroitin sulfate proteoglycan; MAG, myelin-associated glycoprotein; Nogo-A, neurite outgrowth inhibitory protein A; OMgp, oligodendrocyte-myelin glycoprotein; RGM, repulsive guidance molecule; TNF, tumor necrosis factor.



Rho Inhibitor VX-210 in Acute Traumatic Subaxial Cervical Spinal Cord Injury: Design of the SPinal Cord Injury Rho INhibition InvestiGation (SPRING) Clinical Trial

Fehlings Michael G. , Kim Kee D., Aarabi Bizhan, Rizzo Marco, Bond Lisa M., McKerracher Lisa, Vaccaro Alexander R., and Okonkwo David O.

Published Online: 1 May 2018 | <https://doi.org/10.1089/neu.2017.5434>

 Sections  View Article

 Tools  Share

Abstract

Traumatic spinal cord injury (SCI) is associated with a lifetime of disability stemming from loss of motor, sensory, and autonomic functions; these losses, along with increased comorbid sequelae, negatively impact health outcomes and quality of life. Early decompression surgery post-SCI can enhance patient outcomes, but does not directly facilitate neural repair and regeneration. Currently, there are no U.S. Food and Drug Administration–approved pharmacological therapies to augment motor function and functional recovery in individuals with traumatic SCI. After an SCI, the enzyme, Rho, is activated by growth-inhibitory factors and regulates events that culminate in collapse of the neuronal growth cone, failure of axonal regeneration, and, ultimately, failure of motor and functional recovery. Inhibition of Rho activation is a potential treatment for injuries such as traumatic SCI. VX-210, an investigational agent, inhibits Rho. When administered extradurally after decompression (corpectomy or laminectomy) and stabilization surgery in a phase 1/2a study, VX-210 was well tolerated. Here, we describe the design of the SPRING trial, a multicenter, phase 2b/3, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of VX-210 (NCT02669849). A subset of patients with acute traumatic cervical SCI is currently being enrolled in the United States and Canada. Medical, neurological, and functional changes are evaluated at 6 weeks and at 3, 6, and 12 months after VX-210 administration. Efficacy will be assessed by the primary outcome measure, change in upper extremity motor score at 6 months post-treatment, and by secondary outcomes that include question-based and task-based evaluations of functional recovery.

References

1 National Spinal Cord Injury Statistical Center. Spinal cord injury facts and figures at a glance. 2017. Available at: <https://www.nscisc.uab.edu>. Accessed July 14, 2017.

2 SinghA., TetreaultL., Kalsi-RyanS., NouriA., and FehlingsM.G. (2014). Global prevalence and incidence of traumatic spinal cord injury. **Clin. Epidemiol.** 6, 309–331.Medline


3 AarabiB., SansurC.A., IbrahimiD.M., SimardJ.M., HershD.S., LeE., DiazC., MassettiJ., and Akhtar-DaneshN. (2017). Intramedullary lesion length on postoperative magnetic resonance imaging is a strong predictor of ASIA impairment scale grade conversion following decompressive surgery in cervical spinal cord injury. **Neurosurgery** 80, 610–620.Crossref, Medline

4 World Health Organization. Spinal cord injury: fact sheet no. 384. 2013. Available at: <http://www.who.int/mediacentre/factsheets/fs384/en/>. Accessed July 14, 2017.

5 FehlingsM.G., VaccaroA., WilsonJ.R., SinghA., CadotteD.W., HarropJ.S., AarabiB., ShaffreyC., DvorakM., FisherC., ArnoldP., MassicotteE.M., LewisJ., and RampersaudR. (2012). Early versus



Rho Inhibitor VX-210 in Acute Traumatic Subaxial Cervical Spinal Cord Injury: Design of the SPinal Cord Injury Rho INhibition InvestiGation (SPRING) Clinical Trial

Fehlings Michael G.  Kim Kee D., Aarabi Bizhan, Rizzo Marco, Bond Lisa M., McKerracher Lisa, Vaccaro Alexander R., and Okonkwo David O.

Published Online: 1 May 2018 | <https://doi.org/10.1089/neu.2017.5434>

 Sections  View Article

 Tools  Share

Abstract

Traumatic spinal cord injury (SCI) is associated with a lifetime of disability stemming from loss of motor, sensory, and autonomic functions; these losses, along with increased comorbid sequelae, negatively impact health outcomes and quality of life. Early decompression surgery post-SCI can enhance patient outcomes, but does not directly facilitate neural repair and regeneration. Currently, there are no U.S. Food and Drug Administration–approved pharmacological therapies to augment motor function and functional recovery in individuals with traumatic SCI. After an SCI, the enzyme, Rho, is activated by growth-inhibitory factors and regulates events that culminate in collapse of the neuronal growth cone, failure of axonal regeneration, and, ultimately, failure of motor and functional recovery. Inhibition of Rho activation is a potential treatment for injuries such as traumatic SCI. VX-210, an investigational agent, inhibits Rho. When administered extradurally after decompression (corpectomy or laminectomy) and stabilization surgery in a phase 1/2a study, VX-210 was well tolerated. Here, we describe the design of the SPRING trial, a multicenter, phase 2b/3, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of VX-210 (NCT02669849). A subset of patients with acute traumatic cervical SCI is currently being enrolled in the United States and Canada. Medical, neurological, and functional changes are evaluated at 6 weeks and at 3, 6, and 12 months after VX-210 administration. Efficacy will be assessed by the primary outcome measure, change in upper extremity motor score at 6 months post-treatment, and by secondary outcomes that include question-based and task-based evaluations of functional recovery.

Recommended

Rodent Neural Progenitor Cells Support Functional Recovery after Cervical Spinal Cord Contusion

Brock John HoffmanGraham LoriStaufenberg Eileen Im SarahTuszynski Mark Henry

VOL. 35, NO. 9, MAY 2018

A Community Perspective on Bowel Management and Quality of Life after Spinal Cord Injury: The Influence of Auto ...

Inskip Jessica A.Lucci Vera-Ellen M. McGrath Maureen S.Willms Rhonda ...

VOL. 35, NO. 9, MAY 2018

Predicting Injury Severity and Neurological Recovery after Acute Cervical Spinal Cord Injury: A Comparison of Cerebrospinal Flui ...

Dalkilic TurkerFallah NaderNoonan Vanessa K. Salimi Elizei SanamDong KevinBelanger Lise ...

VOL. 35, NO. 3, FEBRUARY 2018

Xenon Protects against Blast-Induced Traumatic Brain Injury in an *In Vitro* Model

Campos-Pires RitaKoziakova MariiaYonis Amina Pau AshniMacdonald WarrenHarris Katie ...

VOL. 35, NO. 8, APRIL 2018

Mary Ann Liebert, Inc.  publishers

**Biotechnology
and
Regenerative
Medicine**



**Biomedical
Research**



**Clinical
Medicine**



**Engineering
and
Technology**



**Environmental Studies
Integrative Medicine
Law and Policy
Nursing
Public Health
Surgery**



Thank you !

www.ebsco.co.kr

TEL: 02-598-2571